Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 R784G||colorectal cancer||predicted - resistant||Cetuximab||Case Reports/Case Series||Actionable||In a clinical study, ERBB2 R784G was identified in all 11 colorectal cancer patients who were resistant to Erbitux (cetuximab) treatment, and was associated with decreased survival rate (PMID: 30549033).||30549033|